g 744

G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthritis.

Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for the target protein AKT used in PROTAC, binding to lenalidomide, a ligand of ubiquitin E3 ligase cereblon (CRBN), via a ten-hydrocarbon linker to form INY-03-041 for AKT degradation[1].

Ipatasertib-NH2 dihydrochloride is a ligand for the target protein AKT in PROTAC INY-03-041. INY-03-041 consists of Ipatasertib-NH2, a ten-hydrocarbon linker, and the CRBN ligand Lenalidomide, which acts as an E3 ubiquitin ligase.

Ipatasertib (GDC-0068) 是选择性的，ATP 竞争性的pan-Akt 抑制剂，能够抑制Akt1 (IC50:5 nM)，Akt2 (IC50:18 nM)，Akt3 (IC50:8 nM)。Ipatasertib (GDC-0068)可以通过抑制Akt导致p53非依赖性PUMA激活，从而同步激活FoxO3a和NF-κB，直接与 PUMA启动子结合，上调 PUMA 转录和 Bax 介导的内在线粒体凋亡。

BMS-986034 is a GPR119 agonist.

Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) 是一种人源化单克隆抗体，靶向膜表达IgE的M1-prime片段，耗竭记忆B细胞和降低血清IgE。可用于研究哮喘。

Vofatamab (B-701) 是一种全人源靶向 FGFR3 的单克隆抗体。Vofatamab 具有潜在的抗癌抗肿瘤活性，常与其他化合物联用来治疗癌症。